论文信息 - Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.

[1] L. Recht,et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas , 2003, Cancer.

[2] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[3] M. Glantz,et al. Neurologic complications of radiation therapy. , 2003, Neurologic clinics.

[4] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[5] L. Deangelis,et al. Brain Tumors , 2019, Imaging Gliomas After Treatment.

[6] P. Box. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2005 .

[7] Reto Meuli,et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.